HIVVaccineEnterprise retweeted
Yesterday J&J and partners announced the discontinuation of the Imbokodo #HIV Vaccine Trial. Despite this disappointing news, IAS emphasizes the importance of continued investment and engagement in trials to find an effective vaccine. Read our statement: https://nitter.cf/t.co/20IU04Hm25
The Imbokodo trial must drive us to adequately join efforts to find an #HIVVaccine. Read the latest IAS Statement on yesterday's decision to cease the large-scale Imbokodo HIV Vaccine Trial: https://nitter.cf/t.co/a1MWVLpV5K
3
Only with an effective HIV vaccine can we overcome bottlenecks of cure and prevention availability especially for vulnerable communities. "There must be a role for community throughout the whole process from start to finish." @EamonnMurphy @UNAIDS
When it comes to the distribution of an HIV vaccine, we need to fight inequalities and should learn from lessons covid taught us
@IAVI
we need to reignite the enthusiasm and optimism to build capacity and funding to succeed in the search for an HIV vaccine
@UNAIDS
3
Terrific session with an update on progress so far and the future quest for an HIV vaccine. We need one.
Thanks to the speakers for sharing insightful perspectives!
@Kundai Chinyenze @yazdanpanah_y @rbaggaley @Daisy Ouya @Jerome Singh @Paul Stoffels @UNAIDS @HIVpxresearch
2
Eamonn Murphy from @UNAIDS The sustainability element of an #HIV vaccine is key. We need to harness the momentum, the optimism from the #COVID-19 vaccines, and the make the role of #community central from start to finish. #IAS2021
Clinical Protocol and Population Considerations - ppt download slideplayer.com/slide/142731…
HIVVaccineEnterprise retweeted
Our July issue is out! Featuring #HIV vaccines, PrEP for MSM in west Africa and age patterns of HIV incidence in eastern and southern Africa: thelancet.com/journals/lanhi…
Cover by @AsifHazem
BACK TO THE FUTURE: HIV VACCINE LEARNINGS: leading investigators discussed proposed research areas to deepen our understanding of regimens tested in HVTN 702 and other efficacy studies. buff.ly/3xg9JX7
BACK TO THE FUTURE: HIV VACCINE LEARNINGS: Introduction to the workshop where Leading investigators discussed proposed research areas to deepen our understanding of regimens tested in HVTN 702 and other efficacy studies. buff.ly/3xg9JX7
1
BACK TO THE FUTURE: HIV VACCINE LEARNINGS: Innate Immune Analyses - Erica Andersen-Nissen, PhD – Cape Town HVTN Immunology Laboratory, Fred Hutchinson Cancer Research Center. buff.ly/3xg9JX7
An HIV Vaccine: An Unfulfilled Promise? Listen to Dr. Linda-Gail Bekker and Ms. Maureen Luba discuss why an HIV vaccine remains the ultimate game-changer to ending the epidemic and the gaps it will address in the expanding HIV prevention landscape. buff.ly/3wgF5gb
Mucosal Immune Activation in the Female Genital Tract in HVTN702 and RV144 (RV306): A Potential Risk Factor of HIV acquisition in HIV efficacy trials? BACK TO THE FUTURE: HIV VACCINE LEARNINGS buff.ly/3xg9JX7







